Compare NET & VRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NET | VRTX |
|---|---|---|
| Founded | 2009 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | EDP Services |
| Sector | Technology | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 124.3B | 128.8B |
| IPO Year | 2019 | 2006 |
| Metric | NET | VRTX |
|---|---|---|
| Price | $360.60 | $504.13 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 34 | 32 |
| Target Price | $336.81 | ★ $571.39 |
| AVG Volume (30 Days) | ★ 2.6M | 858.7K |
| Earning Date | 10-29-2026 | 11-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 836.54 |
| EPS | N/A | ★ 8.33 |
| Revenue | $2,167,937,000.00 | ★ $2,488,652,000.00 |
| Revenue This Year | $32.46 | $10.39 |
| Revenue Next Year | $28.71 | $9.83 |
| P/E Ratio | ★ N/A | $60.90 |
| Revenue Growth | 29.85 | ★ 46.20 |
| 52 Week Low | $158.83 | $400.86 |
| 52 Week High | $367.43 | $560.25 |
| Indicator | NET | VRTX |
|---|---|---|
| Relative Strength Index (RSI) | 64.39 | 39.15 |
| Support Level | $163.46 | $501.01 |
| Resistance Level | $367.43 | $506.93 |
| Average True Range (ATR) | 16.35 | 11.39 |
| MACD | 0.78 | -1.85 |
| Stochastic Oscillator | 87.34 | 22.70 |
Cloudflare is a software company based in San Francisco, California, that offers security and web performance offerings by utilizing a distributed, serverless content delivery network, or CDN. The firm's edge computing platform, Workers, builds on this infrastructure by enabling clients to deploy and run code without the need to manage or maintain servers.
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.